Shockwave Buys Neovasc, Hoping Reducer Angina Device Complements Coronary Lithotripsy
Executive Summary
Shockwave, which markets lithotripsy technology to treat calcified vascular disease, will pay about $100m upfront and up to $47m more in potential milestones to buy Neovasc, the Vancouver, BC-based developer of the Reducer device to treat angina.
You may also be interested in...
Johnson & Johnson Poised To Lead Multiple Cardiovascular Markets With Shockwave Medical Acquisition
J&J’s acquisition of IVL device maker Shockwave Medical for $13.1bn sets J&J’s medtech arm solidly in a leadership position in multiple cardiovascular markets.
JPM 2024 Roundup: Abbott And Medtronic Push Diabetes Tech, Edwards Updates Tricuspid Progress, Shockwave Bets On R&D
Medtech Insight covered the major announcements from medtech companies during the J.P. Morgan Healthcare Conference in early January. Here are a few more highlights from companies that may not have made the headlines but will, no doubt, make noise in 2024.
Cardio Conversations: AVS' Talks About Starting A Company In A Pandemic, Cracking Peripheral Plaques And More
In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Robert Chisena, the co-founder and CTO of AVS (Amplitude Vascular Systems) where leads research and product development. He talked about his company's novel interventional technology for calcified peripheral arterial disease and how the company came together despite the pandemic.